<?xml version="1.0" encoding="UTF-8"?>
<p id="Par31">A cell-grown, reverse genetics produced wild-type (H1N1)pdm09 influenza A virus was used for intranasal challenge. This GMP-manufactured challenge virus was developed in NIAID by the LID Clinical Studies Unit and has been described in previous trials
 <sup>
  <xref ref-type="bibr" rid="CR22">22</xref>,
  <xref ref-type="bibr" rid="CR33">33</xref>
 </sup>. A total of 10
 <sup>7</sup> TCID
 <sub>50</sub> of challenge virus in sterile saline was delivered in two 500 μl preferred term doses intranasally using the MAD
 <sup>TM</sup> Nasal sprayer device (Wolfe-Tory Medical, Inc., Salt Lake City, UT).
</p>
